Skip to main content
NCBI home page
Springer logoLink to Springer
. 2019 May 14;37(8):1071. doi: 10.1007/s40273-019-00809-1

Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia

Mark Bounthavong 1, Javed Butler 2, Chantal M Dolan 3, Jeffrey D Dunn 4, Kathryn A Fisher 3, Nina Oestreicher 5,6, Bertram Pitt 7, Paul J Hauptman 8, David L Veenstra 1,✉
PMCID: PMC6830401  PMID: 31089966

Correction to: PharmacoEconomics (2018) 36(12):1463–1473 10.1007/s40273-018-0709-3

Page 1467, Section 3 (Results), 1st paragraph, final sentence:

The sentence should read, “In addition, the patiromer-spironolactone-ACEI arm was associated with 0.19 greater total expected QALYs gained than the ACEI-only arm (2.79 versus 2.60 QALYs, respectively).”

Articles from Pharmacoeconomics are provided here courtesy of Springer

RESOURCES